News & Updates

In a systematic review and network meta-analysis (NMA), a statin-ezetimibe combination yields a more favourable LDL-C reduction and a positive trend in atherosclerotic plaque regression compared with PCSK9 inhibitors (PCSK9is) alone in individuals with acute coronary syndrome (ACS).

Young-onset diabetes (YOD) costs Hong Kong more than USD 400 million annually in productivity, researchers from the Chinese University of Hong Kong (CUHK) have reported.

A phase III randomized clinical trial (RCT) of 1,050 patients with hormone receptor–positive (HR-positive), ERBB2-negative advanced breast cancer (ABC) showed that first-line (1L) use of cyclin-dependent kinase (CDK) 4 and 6 inhibitors did not improve overall survival (OS) compared with second-line (2L) use. At the same time, a post hoc subgroup analysis suggested an OS benefit with 1L use of CDK4/6 inhibitors in premenopausal patients.

The final overall survival (OS) analysis of the phase III ROSELLA clinical trial reports an increase of 4.1 months in median OS in patients with platinum-resistant ovarian cancer who received relacorilant in addition to nab-paclitaxel vs those who received nab-paclitaxel alone.

Treatment with deuruxolitinib, an oral Janus kinase 1/2 inhibitor, resulted in significant hair regrowth on the scalp for 24 weeks among patients with severe alopecia areata (AA), according to the two phase III THRIVE-AA1 and -AA2 trials presented at AAD 2026.